The US FDA's portfolio has grown significantly since Scott Gottlieb's first two stints at the agency during the early and mid-2000s. But the outgoing agency head credited the restructuring of the Office of The Commissioner for being able to efficiently manage its various functions.
Speaking at the Brookings Institute March 19, Gottlieb, who will likely depart FDA April 5, alluded to his decision to have the center directors report to him directly, which
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?